TESARO Company Profile (NASDAQ:TSRO)

About TESARO

TESARO logoTESARO, Inc. is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform. It offers VARUBI (rolapitant), which is an oral substance P/neurokinin 1 (NK-1) receptor antagonist for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. It is developing IV formulation of rolapitant, which has completed various Phase 1 clinical trials. Its niraparib is an orally active and poly (ADP-ribose) polymerase (PARP) inhibitor. Its immuno-oncology platform has immuno-oncology programs, which include TSR-022 and TSR-042.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: TSRO
  • CUSIP: 88156910
Key Metrics:
  • Previous Close: $190.36
  • 50 Day Moving Average: $156.19
  • 200 Day Moving Average: $123.60
  • 52-Week Range: $51,662,000.00 - $35.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -31.00
  • P/E Growth: -1.03
  • Market Cap: $9.83B
  • Outstanding Shares: 51,662,000
  • Beta: 1.51
Profitability:
  • Net Margins: -798.68%
  • Return on Equity: -141.88%
  • Return on Assets: -79.30%
Debt:
  • Debt-to-Equity Ratio: 0.26%
  • Current Ratio: 11.59%
  • Quick Ratio: 11.38%
Additional Links:
Companies Related to TESARO:

Analyst Ratings

Consensus Ratings for TESARO (NASDAQ:TSRO) (?)
Ratings Breakdown: 6 Hold Ratings, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.65)
Consensus Price Target: $164.93 (13.36% downside)

Analysts' Ratings History for TESARO (NASDAQ:TSRO)
Show:
DateFirmActionRatingPrice TargetDetails
2/17/2017Morgan StanleyReiterated RatingPositiveView Rating Details
2/17/2017RBC Capital MarketsBoost Price TargetOutperform$142.00 -> $202.00View Rating Details
2/17/2017Royal Bank Of CanadaBoost Price TargetOutperform$142.00 -> $202.00View Rating Details
2/16/2017FBR & CoDowngradeOutperform -> Market Perform$151.00 -> $202.00View Rating Details
2/10/2017Leerink SwannDowngradeOutperform -> Market Perform$186.00View Rating Details
2/9/2017Citigroup Inc.Boost Price TargetBuy$151.00 -> $232.00View Rating Details
2/9/2017SunTrust Banks, Inc.Reiterated RatingBuy -> Average$190.00View Rating Details
2/6/2017Cowen and CompanyInitiated CoverageMarket Perform$155.00View Rating Details
1/19/2017Bank of America CorpBoost Price Target$149.26 -> $165.00View Rating Details
1/14/2017WedbushReiterated RatingOutperform$139.00 -> $166.00View Rating Details
1/12/2017Credit Suisse GroupSet Price TargetBuy$151.00View Rating Details
12/22/2016Robert W. BairdReiterated RatingOutperform$127.00View Rating Details
11/7/2016Lake Street CapitalReiterated RatingBuy$114.00 -> $150.00View Rating Details
11/4/2016Raymond James Financial, Inc.Reiterated RatingOutperform -> Market PerformView Rating Details
8/5/2016Jefferies Group LLCSet Price TargetHold$75.00 -> $80.00View Rating Details
8/5/2016MizuhoLower Price TargetBuy$100.00 -> $94.00View Rating Details
6/30/2016Wells Fargo & CompanyReiterated RatingOutperformView Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for TESARO (NASDAQ:TSRO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017        
11/3/2016Q3($1.92)($1.98)$4.39 million$3.73 millionViewN/AView Earnings Details
5/5/2016Q1($1.69)($2.22)$2.48 million$0.31 millionViewN/AView Earnings Details
2/25/2016Q4($1.63)($1.89)$3.45 million$0.23 millionViewListenView Earnings Details
10/29/2015Q315($1.52)($1.66)ViewListenView Earnings Details
8/6/2015Q215($1.14)($1.51)ViewListenView Earnings Details
4/30/2015Q115($1.12)($1.30)ViewListenView Earnings Details
2/19/2015Q414($1.03)($1.33)ViewListenView Earnings Details
11/5/2014Q314($1.04)($1.01)ViewN/AView Earnings Details
7/24/2014Q214($0.87)($1.03)ViewN/AView Earnings Details
4/30/2014Q114($1.06)($1.43)ViewN/AView Earnings Details
2/19/2014Q413($0.78)($0.72)ViewN/AView Earnings Details
11/7/2013Q313($0.69)($0.88)ViewN/AView Earnings Details
7/25/2013Q2 2013($0.63)($0.67)ViewN/AView Earnings Details
4/25/2013Q1 2013($0.62)($0.66)ViewN/AView Earnings Details
2/14/2013Q4 2012($0.65)($15.41)ViewN/AView Earnings Details
10/25/2012($0.55)($0.52)ViewN/AView Earnings Details
7/26/2012($0.55)($4.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for TESARO (NASDAQ:TSRO)
Current Year EPS Consensus Estimate: $-7.42 EPS
Next Year EPS Consensus Estimate: $-6.14 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($1.69)($1.59)($1.64)
Q2 20162($1.69)($1.58)($1.64)
Q3 20165($1.97)($1.49)($1.72)
Q4 20166($2.03)($1.54)($1.79)
Q1 20174($2.22)($1.81)($1.99)
Q2 20174($1.97)($1.28)($1.71)
Q3 20174($2.23)($1.57)($1.85)
Q4 20174($1.57)($0.82)($1.30)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for TESARO (NASDAQ:TSRO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for TESARO (NASDAQ:TSRO)
Insider Ownership Percentage: 40.50%
Institutional Ownership Percentage: 98.48%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/3/2017Martin H. Jr. HuberSVPSell190$136.26$25,889.40View SEC Filing  
11/2/2016Martin H Jr. HuberSVPSell327$121.29$39,661.83View SEC Filing  
9/22/2016Martin H Jr. HuberSVPSell408$108.12$44,112.96View SEC Filing  
9/8/2016Edward C EnglishVPSell7,000$88.54$619,780.00View SEC Filing  
8/30/2016Jeffrey H HankeVPSell29,166$86.04$2,509,442.64View SEC Filing  
6/30/2016Jeffrey H HankeVPSell12,500$74.35$929,375.00View SEC Filing  
6/10/2016Edward C EnglishVPSell7,000$40.75$285,250.00View SEC Filing  
3/18/2016Arnold L OronskyDirectorBuy142,085$35.19$4,999,971.15View SEC Filing  
3/18/2016Enterprise Associates 13 L NewMajor ShareholderBuy710,429$35.19$24,999,996.51View SEC Filing  
3/10/2016Edward C EnglishVPSell7,000$43.71$305,970.00View SEC Filing  
12/10/2015Edward C. EnglishVPSell17,000$50.19$853,230.00View SEC Filing  
9/8/2015James O ArmitageDirectorBuy500$54.63$27,315.00View SEC Filing  
12/12/2014James O ArmitageDirectorBuy1,000$38.16$38,160.00View SEC Filing  
9/29/2014Lawrence M AllevaDirectorBuy1,100$26.17$28,787.00View SEC Filing  
7/31/2013Lawrence M AllevaDirectorBuy1,449$34.33$49,744.17View SEC Filing  
6/5/2013Peter J BarrisMajor ShareholderSell3,583$39.00$139,737.00View SEC Filing  
4/30/2013Lawrence M AllevaDirectorBuy1,050$28.10$29,505.00View SEC Filing  
11/1/2012Lawrence M AllevaDirectorBuy3,240$15.45$50,058.00View SEC Filing  
8/30/2012Leon O Moulder JrCEOBuy10,000$11.69$116,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for TESARO (NASDAQ:TSRO)
DateHeadline
finance.yahoo.com logoTesaro downgraded by FBR & Co. (NASDAQ:TSRO)
finance.yahoo.com - February 16 at 8:13 PM
finance.yahoo.com logoTesaro to Announce Fourth-Quarter 2016 Financial Results on February 28, 2017 (NASDAQ:TSRO)
finance.yahoo.com - February 15 at 6:37 AM
thestreet.com logoMorgan Stanley, Twitter, Tesaro: Doug Kass' Views (NASDAQ:TSRO)
www.thestreet.com - February 13 at 1:18 AM
us.rd.yahoo.com logoTesaro Explores Possible Sale With Investment Bank (NASDAQ:TSRO)
us.rd.yahoo.com - February 12 at 2:02 AM
us.rd.yahoo.com logoLeerink Cuts Tesaro To Hold After Takeover Speculation Rally (NASDAQ:TSRO)
us.rd.yahoo.com - February 12 at 2:02 AM
News IconBuy or Sell? What Analysts Recommends: Tesaro, Inc. (TSRO), Darden Restaurants, Inc. (DRI) - StockNewsJournal (NASDAQ:TSRO)
stocknewsjournal.com - February 11 at 6:57 AM
investors.com logoTesaro's Rumored Sale Could Fetch North Of $200 Per Share: Analysts (NASDAQ:TSRO)
www.investors.com - February 11 at 6:57 AM
fool.com logoHere's Why M&A Has Tesaro's Stock Soaring 40% In 2017 (NASDAQ:TSRO)
www.fool.com - February 10 at 4:41 PM
News IconAnalytical Guide for Helmerich & Payne, Inc. (HP), Tesaro, Inc. (TSRO) Stakeholders - The USA Commerce (NASDAQ:TSRO)
theusacommerce.com - February 10 at 6:16 AM
bizjournals.com logoTesaro shares skyrocket on report of buyout interest from drugmakers (NASDAQ:TSRO)
us.rd.yahoo.com - February 9 at 6:18 AM
us.rd.yahoo.com logoTesaro Rockets To All-Time High On Rumored Takeover Interest (NASDAQ:TSRO)
us.rd.yahoo.com - February 9 at 6:18 AM
fool.com logoWhy Panera Bread, Tesaro, and Universal Corp. Jumped Today (NASDAQ:TSRO)
www.fool.com - February 8 at 4:53 PM
News IconEquities Analysts Offer Predictions for TESARO, Inc.’s Q2 2017 Earnings (TSRO) (NASDAQ:TSRO)
forextv.com - February 8 at 8:08 AM
feeds.benzinga.com logoTesaro Announces Participation at Two Investor Conferences (NASDAQ:TSRO)
feeds.benzinga.com - February 2 at 5:37 PM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in Tesaro (TSRO) Stock? (NASDAQ:TSRO)
finance.yahoo.com - February 2 at 6:14 AM
News IconTesaro - Chart Of The Day (NASDAQ:TSRO)
www.talkmarkets.com - February 1 at 7:04 AM
News IconTime to Reconsider TESARO Inc (TSRO) After Achieving 52-Week High? (NASDAQ:TSRO)
randolphguide.com - February 1 at 7:04 AM
News IconClovis Oncology Inc (CLVS)’s Ovarian Cancer Drug Faces Stiff Competition From AstraZeneca PLC (ADR) (AZN), TESARO Inc (TSRO) (NASDAQ:TSRO)
feedproxy.google.com - January 31 at 2:16 PM
News IconHigh Volatility Creating Buzz Mid-Session For Tesaro, Inc. (NASDAQ:TSRO) - Wall Street Beacon (NASDAQ:TSRO)
wsbeacon.com - January 28 at 7:07 AM
News IconEarnings in Full Force, Analysts Take Aim at TESARO, Inc. (NASDAQ:TSRO) - Wall Street Beacon (NASDAQ:TSRO)
wsbeacon.com - January 28 at 7:07 AM
News IconThe Technical Facts on Tesaro, Inc. (TSRO) - The USA Commerce (NASDAQ:TSRO)
theusacommerce.com - January 28 at 7:07 AM
bloomberg.com logoBloomberg Markets: Dave Wilson’s Stock of the Day for Jan. 26 (NASDAQ:TSRO)
www.bloomberg.com - January 27 at 6:22 AM
fool.com logoHere's the Reason Behind TESARO Inc.'s Sudden 12% Move Higher (NASDAQ:TSRO)
www.fool.com - January 26 at 3:26 PM
marketnewsvideo.com logoNoteworthy Wednesday Option Activity: PNRA, TSRO, HLF (NASDAQ:TSRO)
www.marketnewsvideo.com - January 26 at 6:29 AM
rttnews.com logoBiotech Stocks Facing FDA Decision In February (NASDAQ:TSRO)
www.rttnews.com - January 26 at 6:29 AM
nasdaq.com logoCommit To Buy Tesaro At $80, Earn 11.2% Using Options (NASDAQ:TSRO)
www.nasdaq.com - January 20 at 7:17 AM
investors.com logoBiotech Stocks Might Catalyze, Or Plunge, On 4 Key Sectors In 2017 (NASDAQ:TSRO)
www.investors.com - January 20 at 7:17 AM
streetinsider.com logoTESARO (TSRO) Niraparib EAP Opens in U.S. for Ovarian Cancer (NASDAQ:TSRO)
www.streetinsider.com - January 18 at 3:23 AM
proactiveinvestors.co.uk logoClinigen launches managed access program for US pharma giant (NASDAQ:TSRO)
www.proactiveinvestors.co.uk - January 17 at 10:35 AM
us.rd.yahoo.com logoCoverage initiated on Tesaro by Morgan Stanley (NASDAQ:TSRO)
us.rd.yahoo.com - January 14 at 6:42 AM
News IconThe Three Most Important Questions For TESARO Inc (TSRO) Shareholders Right Now (NASDAQ:TSRO)
feedproxy.google.com - January 13 at 11:20 AM
News IconTesaro Craters as the FDA Denies Approval of Rolapitant IV (NASDAQ:TSRO)
www.biospace.com - January 13 at 2:16 AM
News IconFDA Denies Approval of Tesaro’s Rolapitant IV (NASDAQ:TSRO)
www.pharmalive.com - January 13 at 2:16 AM
streetinsider.com logoTESARO (TSRO) Receives FDA CRL for Rolapitant IV NDA (NASDAQ:TSRO)
www.streetinsider.com - January 13 at 2:16 AM
finance.yahoo.com logoTESARO Receives Complete Response Letter for Rolapitant IV from U.S. FDA (NASDAQ:TSRO)
finance.yahoo.com - January 13 at 2:16 AM
finance.yahoo.com logo3:34 am Tesaro receives Complete Response Letter for Rolapitant IV; co is working expeditiously to provide the requested information (NASDAQ:TSRO)
finance.yahoo.com - January 13 at 2:16 AM
bizjournals.com logoLatest drug by Waltham drugmaker Tesaro rejected by FDA (NASDAQ:TSRO)
www.bizjournals.com - January 13 at 2:16 AM
biz.yahoo.com logoTESARO, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:TSRO)
biz.yahoo.com - January 13 at 2:16 AM
investors.com logoTesaro Stock Rebounds Despite FDA Holdup On Anti-Nausea Med (NASDAQ:TSRO)
www.investors.com - January 13 at 2:16 AM
feeds.benzinga.com logoTesaro Shares Lower On Receipt Of FDA Complete Response Letter (NASDAQ:TSRO)
feeds.benzinga.com - January 12 at 12:16 PM
News IconStock Reaching Most Volatile List Today: Tesaro, Inc. (NASDAQ:TSRO) - Wall Street Beacon (NASDAQ:TSRO)
wsbeacon.com - January 12 at 5:53 AM
marketexclusive.com logoAnalyst Activity – Leerink Swann Reiterates Outperform on TESARO (NASDAQ:TSRO) (NASDAQ:TSRO)
marketexclusive.com - January 10 at 2:55 AM
biz.yahoo.com logoTESARO, INC. Files SEC form 8-K, Results of Operations and Financial Condition (NASDAQ:TSRO)
biz.yahoo.com - January 10 at 2:54 AM
News IconTesaro Inc TSRO Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:TSRO)
www.bioportfolio.com - January 6 at 6:16 AM
News IconWhat We’re Watching In Biotech For January: Otonomy Inc (OTIC) And TESARO Inc (TSRO) (NASDAQ:TSRO)
feedproxy.google.com - January 3 at 3:20 PM
forbes.com logoAndreas Halvorsen Vs. The Shorts: Five Surprising Holdings (NASDAQ:TSRO)
www.forbes.com - December 28 at 8:12 PM
forbes.com logoEight Milestones Of 2016 In The War On Cancer (NASDAQ:TSRO)
www.forbes.com - December 28 at 8:43 AM
marketexclusive.com logoAnalyst Activity – Robert W. Baird Reiterates Outperform on Tesaro (NASDAQ:TSRO) (NASDAQ:TSRO)
marketexclusive.com - December 23 at 2:33 AM
capitalcube.com logoTESARO, Inc. – Value Analysis (NASDAQ:TSRO) : December 21, 2016 (NASDAQ:TSRO)
www.capitalcube.com - December 22 at 5:26 AM
schaeffersresearch.com logoStocks On the Move: Fred's, Inc., Akebia Therapeutics Inc, and TESARO Inc - Schaeffers Research (blog) (NASDAQ:TSRO)
www.schaeffersresearch.com - December 21 at 2:53 AM

Social

What is TESARO's stock symbol?

TESARO trades on the NASDAQ under the ticker symbol "TSRO."

Where is TESARO's stock going? Where will TESARO's stock price be in 2017?

17 brokerages have issued 12 month price objectives for TESARO's stock. Their forecasts range from $80.00 to $232.00. On average, they expect TESARO's share price to reach $164.93 in the next year.

When will TESARO announce their earnings?

TESARO is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.

What are analysts saying about TESARO stock?

Here are some recent quotes from research analysts about TESARO stock:

  • According to Zacks Investment Research, "Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company's product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts. " (10/11/2016)

  • Credit Suisse Group analysts commented, "Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0 percent POS for now but we conservatively see at least another $1 billion in sales from PARP expansion," analyst Alethia Young wrote in a note."For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50–75 percent and R&D synergies of 15–30 percent. In our base case TSRO P&L we model a tax rate of 30 percent so there could be synergies here as well," Young added.Young also sees further upside to valuation in the long-term from:"PARP expansion in other platinum sensitive tumors."Potential HRD- sales in 1L as we expect the company will amend the protocol."Readouts in breast cancer PARP studies in '17."Immuno-oncology where we expect early data over 2017." (10/10/2016)

  • Wedbush analysts commented, "sees the clinical benefit of niraparib in HRD-negative patients as likely leading to approval in the entire platinum-sensitive ovarian market."Waltham, Massachusetts-based TESARO, has an approved product in Varubi (rolapitant) for the prevention of delayed nausea and vomiting associated with emetogenic chemotherapy. The company is also developing its Phase 3 asset, niraparib, a PARP inhibitor in ovarian and breast cancer indications.TESARO said it would file NDA and MAA for all patients with recurrent, platinum-sensitive ovarian cancer in the fourth quarter 2016."[W]e see the lack of requirement for a companion diagnostic for niraparib in these patients as a potential advantage over competing PARP inhibitors," analyst David Nierengarten wrote in a note.Related Link: 16 Stocks Moving In Monday's Pre-Market SessionNierengarten, who expects niraparib to be launched in the United States in mid-2017, now assumes 50 percent peak penetration into the platinum-sensitive market (up from 20 percent) and cuts peak penetration into the platinum-resistant market to 15 percent from a previous 25 percent."These changes raise our 2021 niraparib sales estimate to $2.2 billion (from $1.6 billion), which also includes revenues from metastatic breast cancer gBRCAmut patients," Nierengarten highlighted.The analyst says 50 percent peak market share is achievable given the favorable comparison of niraparib with data from olaparib-treated patients and olaparib being limited to gBRCA patients only. Nierengarten also noted niraparib has first-mover advantage in this treatment setting versus rucaparib."Underwhelming data from rucaparib in the third line setting presented at ESMO gives us greater confidence that niraparib will be the market leader in the earlier line of therapy, especially if a companion diagnostic is required," (10/10/2016)

  • Citigroup Inc. analysts commented, "now more confident about Niraparib approval in ovarian cancer and reimbursement."The 16.3 percent upside is based on the stock's June 29 closing price of $77.40 when the company announced that Niraparib significantly improved progression-free survival for patients with ovarian cancer in a late stage study. "We now see adjusted peak PARP revenues at $800 million vs. $450 million previously as we conservatively increase duration, increase penetration among HRD+ve pts and assign higher probability to HRD +ve ovarian and breast cancer (only gBRCA) revenues," (7/1/2016)

Who owns TESARO stock?

TESARO's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (15.51%), Franklin Resources Inc. (5.89%), Interwest Venture Management Co. (3.91%), State Street Corp (1.91%), Janus Capital Management LLC (1.48%) and Perceptive Advisors LLC (1.33%). Company insiders that own TESARO stock include Arnold L Oronsky, Edward C English, Enterprise Associates 13 L New, James O Armitage, Jeffrey H Hanke and Martin H Jr Huber.

Who sold TESARO stock? Who is selling TESARO stock?

TESARO's stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, State Street Corp, Deerfield Management Co., Asset Management One Co. Ltd., Nicholas Investment Partners LP, Guggenheim Capital LLC, Marshall Wace LLP and Fred Alger Management Inc.. Company insiders that have sold TESARO stock in the last year include Edward C English, Jeffrey H Hanke and Martin H Jr Huber.

Who bought TESARO stock? Who is buying TESARO stock?

TESARO's stock was purchased by a variety of institutional investors in the last quarter, including Interwest Venture Management Co., Perceptive Advisors LLC, Franklin Resources Inc., FMR LLC, Alyeska Investment Group L.P., Castleark Management LLC, Janus Capital Management LLC and Orbimed Advisors LLC. Company insiders that have bought TESARO stock in the last two years include Arnold L Oronsky, Enterprise Associates 13 L New and James O Armitage.

How do I buy TESARO stock?

Shares of TESARO can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of TESARO stock cost?

One share of TESARO stock can currently be purchased for approximately $190.36.

TESARO (NASDAQ:TSRO) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Earnings History Chart

Earnings by Quarter for TESARO (NASDAQ:TSRO)

Dividend History Chart

Dividend Payments by Quarter for TESARO (NASDAQ:TSRO)

Last Updated on 2/19/2017 by MarketBeat.com Staff